ANALYSIS: With an Obermatt 360° View of 80 (better than 80% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock GC Biopharma are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for GC Biopharma. The consolidated Value Rank has an attractive rank of 65, which means that the share price of GC Biopharma is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 65% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 54, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 84. But the company’s financing is risky with a Safety rank of 41. This means 59% of comparable companies have a safer financing structure than GC Biopharma. ...read more